M R Narkewicz

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “540 Impact of elexacaftor-tezacaftor-ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function, and fat malabsorption: Report of PROMISE PEDS GI”.

540 Impact of elexacaftor-tezacaftor-ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function, and fat malabsorption: Report of PROMISE PEDS GI

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01463-7

N/A

0DataRank · unranked

0 citations

Peter Vu, S. Schwarzenberg, Ben Freedman, M R Narkewicz, J. Pittman +4 more

528 Alterations in the fecal microbiota of patients with advanced cystic fibrosis–associated liver disease after 6 months of elexacaftortezacaftor-ivacaftor

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01451-0

N/A

0DataRank · unranked

0 citations

Cassie F. Pope, H. Hayden, C. Miller, S. Salipante, Steven M. Rowe +6 more